Pharmacology, Toxicology and Pharmaceutical Science
Congestive Heart Failure
100%
Dapagliflozin
29%
Biological Marker
17%
Galectin 3
13%
Diseases
12%
Myocardial Disease
11%
Heart Failure with Reduced Ejection Fraction
11%
Cardiovascular Disease
9%
Heart Failure with Preserved Ejection Fraction
8%
Placebo
8%
Heart Infarction
7%
Malignant Neoplasm
7%
Adverse Outcome
7%
Phospholamban
6%
Heart Ventricle Remodeling
6%
Brain Natriuretic Peptide
6%
Fibrosis
5%
Medicine and Dentistry
Congestive Heart Failure
72%
Ejection Fraction
18%
Dapagliflozin
14%
Biological Marker
12%
Cardiovascular System
11%
Cardiology
10%
Heart Failure with Preserved Ejection Fraction
10%
Myocardial Disease
10%
Heart Failure with Reduced Ejection Fraction
9%
Cardiovascular Disease
8%
Malignant Neoplasm
8%
Hazard Ratio
8%
Heart Left Ventricle Ejection Fraction
7%
Heart Function
6%
Phospholamban
6%
Atrial Fibrillation
6%
Oncology
5%
Diseases
5%
Diabetes
5%
Biochemistry, Genetics and Molecular Biology
Galectin-3
10%
Heart Ejection Fraction
10%
Blood Plasma
6%
Phospholamban
6%
Cardiac Muscle Cell
6%
Brain Natriuretic Peptide
5%
N-Terminus
5%
All Cause Mortality
5%